Peking Union Medical College Hospital
PUMCH is China's foremost academic medical centre. Its Department of Pathology sets national standards for surgical pathology and contributes to WHO classification working groups.
Liu Tonghui
GI pathology
Professor Liu Tonghui at PUMCH is head of pathology and an internationally recognised specialist in GI tumour pathology. His contributions to gastric and colorectal cancer staging in Chinese patient cohorts and his work on Chinese adaptation of WHO pathological classification criteria have influenced national pathology standards.
Peking Union Medical College Hospital · VerifiedChen Jie
breast pathology
Professor Chen Jie at PUMCH is a specialist in breast pathology with contributions to HER2 testing standardisation in China. Her work on TIL assessment in triple-negative breast cancer and the Chinese adaptation of ASCO/CAP HER2 testing guidelines has influenced breast cancer pathology practice nationally.
Peking Union Medical College Hospital · VerifiedWang Jian
lymphoma pathology
Dr Wang Jian at PUMCH is a haematopathologist contributing to the diagnosis and classification of B-cell and T-cell lymphomas in Chinese patients. Her work on EBV-associated NK/T-cell lymphoma, which has a higher prevalence in Asian populations, has been published in international haematopathology journals.
Peking Union Medical College Hospital · VerifiedZhu Xishan
molecular pathology
Professor Zhu Xishan at PUMCH contributes to the integration of molecular diagnostics with conventional histopathological diagnosis. Her work on next-generation sequencing panel implementation for oncological specimens has contributed to the development of Chinese precision oncology pathology protocols.
Peking Union Medical College Hospital · VerifiedLiang Zhiyong
gynaecological pathology
Professor Liang Zhiyong at PUMCH is a specialist in gynaecological oncology pathology. His contributions to the WHO classification of female genital tumours and his work on molecular biomarker testing in endometrial and cervical cancer have been influential in Chinese academic pathology.
Peking Union Medical College Hospital · VerifiedXie Shuanghua
neuropathology
Dr Xie Shuanghua at PUMCH contributes to neuropathology, covering brain tumour classification using WHO 2021 CNS criteria and the histopathological and molecular workup of epilepsy surgery specimens in the PUMCH neuroscience centre.
Peking Union Medical College Hospital · VerifiedFeng Lin
liver pathology
Dr Feng Lin at PUMCH is a hepatopathologist contributing to the evaluation of hepatocellular carcinoma, non-alcoholic steatohepatitis grading, and liver transplant pathology at China's leading academic medical centre.
Peking Union Medical College Hospital · VerifiedZhang Lu
lung pathology
Dr Zhang Lu at PUMCH contributes to the classification of NSCLC using WHO 2021 criteria and the implementation of molecular reflex testing panels for EGFR, ALK, ROS1, RET, MET, KRAS, BRAF, and NTRK in thoracic oncology specimens.
Peking Union Medical College Hospital · VerifiedLi Wei
bone & soft tissue pathology
Dr Li Wei at PUMCH is a specialist in bone and soft tissue tumour pathology. His contributions to the diagnosis of novel sarcoma entities and the molecular workup of undifferentiated sarcomas have been presented at national Chinese pathology congresses.
Peking Union Medical College Hospital · VerifiedSun Yang
renal pathology
Dr Sun Yang at PUMCH is a renal pathologist specialising in native and transplant kidney biopsies, contributing to the Chinese implementation of the Oxford MEST-C classification for IgA nephropathy.
Peking Union Medical College Hospital · VerifiedWang Peng
digital pathology
Dr Wang Peng at PUMCH contributes to digital pathology AI development in China. His work on deep learning-based tumour detection and grading in gastric cancer whole-slide images has been published in the Journal of Pathology and npj Digital Medicine.
Peking Union Medical College Hospital · VerifiedLiu Yan
skin pathology
Dr Liu Yan at PUMCH is a dermatopathologist contributing to the classification of melanocytic lesions in Chinese patients and the histopathological diagnosis of inflammatory dermatoses with particular attention to diseases more prevalent in Asian skin.
Peking Union Medical College Hospital · VerifiedHe Jia
cardiovascular pathology
Dr He Jia contributes to cardiovascular pathology at PUMCH, covering endomyocardial biopsies for myocarditis and cardiomyopathy classification and the histopathological evaluation of surgically excised cardiac tumours.
Peking Union Medical College Hospital · VerifiedZhao Ming
head & neck pathology
Dr Zhao Ming at PUMCH contributes to the surgical pathology of head and neck tumours, including salivary gland neoplasms, thyroid nodule evaluation, and the molecular characterisation of nasopharyngeal carcinoma, which has a higher incidence in Chinese populations.
Peking Union Medical College Hospital · VerifiedChen Wei
prostate pathology
Dr Chen Wei at PUMCH contributes to prostate cancer Gleason grading using the ISUP 2014/2019 criteria and to the evaluation of PSMA expression by IHC in prostatectomy specimens for radionuclide therapy eligibility.
Peking Union Medical College Hospital · VerifiedHuang Yi
pancreatic pathology
Dr Huang Yi at PUMCH contributes to the surgical pathology of pancreatic ductal adenocarcinoma and other pancreatic neoplasms, including the characterisation of IPMN multifocality and the pathological assessment of pancreaticoduodenectomy resection margins.
Peking Union Medical College Hospital · VerifiedLi Na
haematopathology
Dr Li Na at PUMCH is a haematopathologist contributing to bone marrow biopsy evaluation for AML and MDS diagnosis and the integrated molecular-morphological classification of myeloid neoplasms.
Peking Union Medical College Hospital · VerifiedXu Hong
pulmonary pathology
Dr Xu Hong at PUMCH contributes to rare lung tumour classification including NUT carcinoma, sarcomatoid carcinoma, and pulmonary LCNEC, applying WHO 2021 diagnostic criteria with molecular correlation.
Peking Union Medical College Hospital · VerifiedWang Xiaohui
paediatric pathology
Dr Wang Xiaohui at PUMCH contributes to paediatric tumour pathology, covering Wilms tumour, neuroblastoma, and childhood leukaemia bone marrow histology within the national paediatric oncology network.
Peking Union Medical College Hospital · VerifiedZhang Wei
forensic pathology
Dr Zhang Wei contributes to forensic pathology in Beijing, covering cause of death determination, traumatic injury histopathological evaluation, and medico-legal autopsy within the Chinese judicial system.
Peking Union Medical College Hospital · VerifiedLiu Bao
molecular oncology
Dr Liu Bao at PUMCH contributes to the implementation of comprehensive genomic profiling from FFPE tissue specimens, supporting the PUMCH molecular tumour board with integrated histopathological-genomic reports.
Peking Union Medical College Hospital · VerifiedChen Hong
GI molecular pathology
Dr Chen Hong at PUMCH contributes to the characterisation of Lynch syndrome in Chinese colorectal cancer patients, including MMR protein IHC testing and MLH1 promoter methylation analysis for sporadic MSI-H CRC.
Peking Union Medical College Hospital · VerifiedQin Yun
ovarian pathology
Dr Qin Yun at PUMCH contributes to the pathological classification of ovarian tumours using WHO 2020 criteria and to the molecular workup of high-grade serous ovarian carcinoma for HRD testing and PARP inhibitor eligibility.
Peking Union Medical College Hospital · VerifiedJiang Tao
GI oncology
Dr Jiang Tao at PUMCH contributes to the pathological characterisation of gastric cancer molecular subtypes (EBV, MSI, SCNA, GS) identified by TCGA and their correlation with clinical outcomes in Chinese patient populations.
Peking Union Medical College Hospital · VerifiedWu Li
interventional pathology
Dr Wu Li at PUMCH contributes to the pathological evaluation of CT-guided biopsy specimens from thoracic, abdominal, and hepatic lesions, including the optimisation of specimen adequacy assessment at the bedside for molecular testing.
Peking Union Medical College Hospital · VerifiedFudan University
Fudan University Shanghai Medical College and its affiliated Zhongshan and Huashan hospitals constitute one of China's foremost academic pathology centres with strengths in liver, brain, and solid tumour pathology.
Zheng Song
surgical pathology
Professor Zheng Song at Fudan University is a leading Chinese surgical oncologist whose translational pathology work covers colorectal cancer surgical resection quality and lymph node harvest assessment. He is a member of the Chinese Anti-Cancer Association surgical pathology committee.
Fudan University · VerifiedZhou Xiaoyan
GI pathology
Professor Zhou Xiaoyan at Fudan Cancer Hospital is a specialist in GI pathology. Her work on the molecular subtyping of colorectal cancer using Chinese population data and her contributions to the Chinese CRC pathology staging guidelines have been widely cited in Chinese oncology literature.
Fudan University · VerifiedYin Hongying
breast pathology
Professor Yin Hongying at Fudan contributes to breast tumour pathology, particularly the molecular classification of triple-negative breast cancer subtypes (BL1, BL2, M, LAR) using Chinese patient datasets, and the pathological characterisation of breast cancer response to neoadjuvant chemotherapy.
Fudan University · VerifiedDu Xiang
haematopathology
Dr Du Xiang at Ruijin Hospital, Shanghai, is a haematologist and haematopathologist contributing to AML-MRC diagnosis, MDS classification, and integrated morphological-cytogenetic-molecular haematopathology in the Shanghai haematology network.
Fudan University · VerifiedShi Guohua
renal pathology
Dr Shi Guohua at Zhongshan Hospital, Fudan, is a renal pathologist contributing to the histopathological evaluation of native and transplant kidney biopsies, including IgA nephropathy, membranous nephropathy, and ANCA vasculitis in Chinese patients.
Fudan University · VerifiedGuo Wei
neuropathology
Dr Guo Wei at Huashan Hospital, Fudan, is a neuropathologist contributing to the WHO 2021 CNS tumour classification implementation and to the histopathological assessment of epilepsy surgery specimens from temporal lobectomy and hemispherectomy procedures.
Fudan University · VerifiedPeng Zhihai
liver pathology
Dr Peng Zhihai at Zhongshan Hospital, Fudan, contributes to HCC pathological staging and the characterisation of early HCC in cirrhotic livers. His work on pathological risk factors for HCC recurrence after resection and transplantation contributes to Chinese liver transplant selection criteria.
Fudan University · VerifiedWang Chunmei
lung pathology
Dr Wang Chunmei at Fudan Cancer Hospital contributes to NSCLC molecular testing and classification, including ALK, ROS1, and RET fusion detection and MET exon 14 skipping mutation testing in Chinese lung cancer patients.
Fudan University · VerifiedChen Xiaosong
thyroid pathology
Dr Chen Xiaosong at Fudan contributes to the diagnostic criteria for thyroid papillary microcarcinoma and the characterisation of molecular markers predictive of aggressive behaviour in low-risk thyroid cancers in Chinese patients.
Fudan University · VerifiedLiu Tianshu
GI oncology
Dr Liu Tianshu at Zhongshan Hospital, Fudan, is a GI oncologist contributing to the pathological characterisation of gastric cancer and colorectal cancer molecular biomarkers in Chinese CSCO-sponsored clinical trials.
Fudan University · VerifiedTang Zhaowei
liver surgery pathology
Dr Tang Zhaowei at Zhongshan Hospital contributes to the surgical pathology of HCC, contributing to microvascular invasion assessment as a pathological predictor of post-resection recurrence in Chinese liver surgery cohorts.
Fudan University · VerifiedYu Yunfei
prostate pathology
Dr Yu Yunfei contributes to prostate cancer Gleason grading and the pathological characterisation of intraductal carcinoma of the prostate at Fudan. His work on the clinical significance of intraductal carcinoma as a prognostic histological finding contributes to Chinese prostate cancer pathology guidelines.
Fudan University · VerifiedNi Xudong
head & neck pathology
Dr Ni Xudong at EENT Hospital, Fudan, contributes to the surgical pathology of head and neck tumours including laryngeal carcinoma, sinonasal undifferentiated carcinoma, and NPC, with particular attention to molecular features predictive of treatment response.
Fudan University · VerifiedWang Weijia
GI pathology
Dr Wang Weijia contributes to the histopathological and molecular characterisation of gastric GIST at Fudan Cancer Hospital. Her work on GIST genotype-phenotype correlation includes the characterisation of SDH-deficient GIST and their histological features in Chinese patient cohorts.
Fudan University · VerifiedZhao Jian
molecular genetics
Dr Zhao Jian at Fudan contributes to cancer genome medicine and the development of Chinese NGS-based molecular pathology testing panels for solid tumours and haematological malignancies.
Fudan University · VerifiedChen Yining
soft tissue pathology
Dr Chen Yining contributes to soft tissue tumour pathology at Fudan, covering synovial sarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. Her work on molecular markers for sarcoma classification contributes to the Fudan sarcoma MDT.
Fudan University · VerifiedDing Yujun
CNS pathology
Dr Ding Yujun at Huashan Hospital contributes to the molecular neuropathology workup of glioma, meningioma, and medulloblastoma using the WHO 2021 integrated classification framework.
Fudan University · VerifiedShen Lingling
GI molecular testing
Dr Shen Lingling at Zhongshan Hospital, Fudan, contributes to the clinical implementation of ctDNA-based liquid biopsy as a complement to tissue pathological diagnosis in colorectal and liver cancer.
Fudan University · VerifiedZhang Xinran
gynaecological pathology
Dr Zhang Xinran at Fudan contributes to the molecular pathological classification of endometrial carcinoma using the TCGA-surrogate four-group system (POLE-ultra, MSI-H, NSMP, p53-abnormal) in Chinese patients.
Fudan University · VerifiedTian Shu
digital pathology
Dr Tian Shu at Fudan contributes to the development and validation of deep learning tools for automated Gleason grading in prostate biopsies and TIL quantification in breast cancer FFPE sections.
Fudan University · VerifiedXu Midie
GI pathology
Dr Xu Midie at Shanghai Tenth People's Hospital, with Fudan ties, contributes to the characterisation of appendiceal neoplasms including low-grade appendiceal mucinous neoplasm (LAMN) and the histopathological assessment of PMP after cytoreductive surgery.
Fudan University · VerifiedLu Weiguo
gynaecological oncology
Professor Lu Weiguo at Zhejiang University, with Fudan collaborative ties, contributes to the pathological staging and biomarker analysis of cervical carcinoma in Chinese randomised clinical trials.
Fudan University · VerifiedChen Jianfei
immunopathology
Dr Chen Jianfei at Fudan contributes to the characterisation of tumour immune microenvironment by multiplex IHC in Chinese solid tumour cohorts, focusing on PD-L1 expression and TIL phenotypes.
Fudan University · VerifiedShao Zhiming
breast oncology
Professor Shao Zhiming at Fudan Cancer Hospital is internationally recognised for his work on the molecular epidemiology of breast cancer in young Chinese women. His pathological research on luminal B and TNBC subtypes in Chinese premenopausal patients has contributed to national treatment guidelines.
Fudan University · VerifiedHuang Jian
urology pathology
Dr Huang Jian at Fudan contributes to urothelial carcinoma staging, histological subtype recognition, and the implementation of FGFR3 and PD-L1 testing in bladder cancer specimens.
Fudan University · VerifiedChinese Academy of Medical Sciences
The Chinese Academy of Medical Sciences and Peking Union Medical College represent China's national medical research and pathology standards body, with affiliated hospitals including the Cancer Hospital.
Lin Dong
cancer pathology
Professor Lin Dong at CAMS Cancer Hospital is a leading Chinese cancer pathologist contributing to the characterisation of lung, oesophageal, and gastric cancer in national clinical trials and to Chinese pathology guideline development.
Chinese Academy of Medical Sciences · VerifiedShen Qi
molecular pathology
Dr Shen Qi at CAMS contributes to the development of molecular pathology testing standards for Chinese hospitals, including EGFR and KRAS mutation testing quality assurance and the national external quality assessment programme for molecular oncology.
Chinese Academy of Medical Sciences · VerifiedJiang Zefei
breast pathology
Professor Jiang Zefei at the 307th Hospital of PLA, with CAMS ties, is a breast oncologist whose translational pathology work covers HER2 testing in Chinese breast cancer patients and the molecular characterisation of locally advanced breast cancer in Chinese CSCO trial cohorts.
Chinese Academy of Medical Sciences · VerifiedLiu Yunpeng
GI oncology
Professor Liu Yunpeng at the First Affiliated Hospital of China Medical University, with CAMS ties, contributes to gastric cancer molecular biomarker research including VEGFR2 and HER2 testing for targeted therapy eligibility.
Chinese Academy of Medical Sciences · VerifiedJia Ning
lung pathology
Dr Jia Ning at CAMS Cancer Hospital contributes to the surgical pathology of thoracic tumours, including the WHO 2021 classification of lung adenocarcinoma and the implementation of molecular reflex testing.
Chinese Academy of Medical Sciences · VerifiedWang Guiqi
oesophageal pathology
Dr Wang Guiqi at CAMS Cancer Hospital contributes to oesophageal squamous cell carcinoma pathology research. China has one of the highest global incidences of OSCC, and his work on the early detection and pathological characterisation of superficial OSCC informs national screening programmes.
Chinese Academy of Medical Sciences · VerifiedZhang Jian
haematopathology
Dr Zhang Jian at CAMS Institute of Haematology, Tianjin, is a haematopathologist contributing to AML, CML, and lymphoma classification at China's foremost dedicated haematology centre.
Chinese Academy of Medical Sciences · VerifiedGuo Jun
melanoma pathology
Professor Guo Jun at Peking University Cancer Hospital, with CAMS ties, is China's leading melanoma specialist. His work on the unique molecular features of acral and mucosal melanoma in Chinese patients — including KIT mutation prevalence — has contributed to Chinese melanoma pathology and treatment guidelines.
Chinese Academy of Medical Sciences · VerifiedChen Ke
breast genetics
Dr Chen Ke at CAMS contributes to hereditary breast cancer pathology research, including BRCA1/2 mutation testing in Chinese familial breast cancer and the characterisation of BRCA-related histological features.
Chinese Academy of Medical Sciences · VerifiedMa Jianxin
lymphoma
Dr Ma Jianxin at CAMS contributes to lymphoma pathological diagnosis and treatment in the national medical centre network, with particular attention to NK/T-cell lymphoma and peripheral T-cell lymphoma subtypes more prevalent in Chinese patients.
Chinese Academy of Medical Sciences · VerifiedYu Hongmei
cervical pathology
Dr Yu Hongmei at CAMS Cancer Hospital contributes to cervical carcinoma staging, HPV genotyping in cervical precancerous lesions, and the pathological evaluation of conisation and radical hysterectomy specimens.
Chinese Academy of Medical Sciences · VerifiedPeng Yi
colorectal pathology
Dr Peng Yi at CAMS contributes to the pathological characterisation of hereditary colorectal cancer syndromes in Chinese families, including familial adenomatous polyposis, Lynch syndrome, and MUTYH-associated polyposis.
Chinese Academy of Medical Sciences · VerifiedWei Yuquan
translational oncology
Professor Wei Yuquan at Sichuan University, with CAMS collaborative ties, contributes to translational cancer pathology research on novel immunotherapy biomarkers in Chinese solid tumour cohorts.
Chinese Academy of Medical Sciences · VerifiedHe Jie
thoracic surgery pathology
Professor He Jie at CAMS Cancer Hospital is China's leading thoracic surgeon whose translational work contributes to the pathological staging of NSCLC and the histological classification of minimally invasive adenocarcinoma.
Chinese Academy of Medical Sciences · VerifiedLi Jian
GI pathology
Dr Li Jian at CAMS contributes to the characterisation of hereditary diffuse gastric cancer (CDH1 mutations) and the pathological criteria for prophylactic gastrectomy eligibility in Chinese HDGC families.
Chinese Academy of Medical Sciences · VerifiedZhao Hong
colorectal surgery
Dr Zhao Hong at CAMS Cancer Hospital contributes to the surgical pathology of colorectal liver metastases, including the characterisation of pathological response to chemotherapy and the correlation of histological response pattern with survival outcomes.
Chinese Academy of Medical Sciences · VerifiedSun Yan
nasopharyngeal carcinoma
Professor Sun Yan at CAMS Cancer Hospital is internationally recognised for his translational work on nasopharyngeal carcinoma. NPC has an exceptionally high incidence in southern China, and his work on EBV-related pathogenesis, histological typing, and molecular biomarkers for NPC has shaped Chinese NPC pathology standards.
Chinese Academy of Medical Sciences · VerifiedSheng Long
haematology molecular pathology
Dr Sheng Long at the CAMS Institute of Haematology contributes to the molecular pathological characterisation of CML beyond BCR-ABL and the diagnosis of BCR-ABL-negative myeloproliferative neoplasms including JAK2, CALR, and MPL-mutant MPN.
Chinese Academy of Medical Sciences · VerifiedWang Lan
reproductive pathology
Dr Wang Lan at CAMS contributes to obstetric and gestational trophoblastic disease pathology, covering the histopathological classification of molar pregnancy, choriocarcinoma, and placental site trophoblastic tumour.
Chinese Academy of Medical Sciences · VerifiedTang Zeyao
thyroid pathology
Dr Tang Zeyao at CAMS contributes to the integration of molecular testing (BRAF V600E, RAS, RET/PTC rearrangements) with conventional thyroid nodule FNA cytology and histopathological classification.
Chinese Academy of Medical Sciences · VerifiedNi Luyao
hepatobiliary pathology
Dr Ni Luyao at CAMS contributes to the pathological classification of biliary tract tumours, including hilar cholangiocarcinoma staging and the histological evaluation of iatrogenic biliary strictures.
Chinese Academy of Medical Sciences · VerifiedChen Nan
lung adenocarcinoma
Dr Chen Nan at CAMS Cancer Hospital contributes to the histopathological grading of lung adenocarcinoma and the characterisation of spread through air spaces as a prognostic histological feature.
Chinese Academy of Medical Sciences · VerifiedLi Fang
skin pathology
Dr Li Fang at CAMS contributes to dermatopathology and the histopathological diagnosis of mycosis fungoides, primary cutaneous DLBCL, and Merkel cell carcinoma within the Chinese dermatopathology quality programme.
Chinese Academy of Medical Sciences · VerifiedQian Jing
urothelial pathology
Dr Qian Jing at CAMS Cancer Hospital contributes to the histopathological staging and molecular testing of urothelial carcinoma, including the FGFR3 and TERT promoter mutation landscape in Chinese bladder cancer populations.
Chinese Academy of Medical Sciences · VerifiedXu Bing
molecular tumour board
Dr Xu Bing at CAMS contributes to the development of the national molecular tumour board programme integrating comprehensive genomic profiling with histopathological diagnosis for Chinese cancer patients.
Chinese Academy of Medical Sciences · VerifiedZhejiang University
Zhejiang University School of Medicine and its affiliated Sir Run Run Shaw Hospital and First Affiliated Hospital represent one of eastern China's foremost academic pathology centres.
Ding Ke-feng
colorectal pathology
Professor Ding Ke-feng at Zhejiang University is a colorectal surgical oncologist whose translational pathology work on peritoneal metastasis treatment and the JCOG/CSCO pathological endpoint analyses from Chinese colorectal cancer cohorts has been widely published.
Zhejiang University · VerifiedShu Yongqian
thoracic oncology
Professor Shu Yongqian at Nanjing Medical University, with Zhejiang collaborative ties, contributes to lung cancer molecular testing standardisation and the characterisation of EGFR resistance mechanisms at the histopathological level.
Zhejiang University · VerifiedChen Zhiwei
immunopathology
Professor Chen Zhiwei at Zhejiang University contributes to cancer immunopathology research on NKT cell activation and its tumour microenvironment correlates in liver and lung cancer histological specimens.
Zhejiang University · VerifiedPan Xuejun
renal oncology
Dr Pan Xuejun at Zhejiang University contributes to the molecular pathology of renal cell carcinoma, including VHL, PBRM1, and BAP1 mutation characterisation in Chinese ccRCC cohorts and their correlation with WHO/ISUP grade.
Zhejiang University · VerifiedZhang Weijin
cardiovascular pathology
Dr Zhang Weijin at Zhejiang University contributes to the histopathological evaluation of endomyocardial biopsies for myocarditis and dilated cardiomyopathy classification at the affiliated cardiac surgery centre.
Zhejiang University · VerifiedWang Yiping
GI pathology
Dr Wang Yiping at Zhejiang University contributes to GI pathology, covering the characterisation of serrated adenomas and the molecular basis of the serrated pathway to colorectal cancer in Chinese populations.
Zhejiang University · VerifiedLi Hanqing
liver transplant pathology
Dr Li Hanqing at Zhejiang First Affiliated contributes to liver transplant pathological diagnosis, including Banff-graded acute rejection, recurrent HBV hepatitis, and post-transplant lymphoproliferative disorder.
Zhejiang University · VerifiedShen Bo
pancreatic pathology
Dr Shen Bo at Zhejiang contributes to the surgical pathology of pancreatic neoplasms, covering PDAC resection specimen assessment, acinar cell carcinoma diagnosis, and PanIN grading in resected pancreata from chronic pancreatitis patients.
Zhejiang University · VerifiedChen Ping
lung pathology
Dr Chen Ping at Zhejiang contributes to the histopathological classification of pleuropulmonary neoplasms including mesothelioma, solitary fibrous tumour, and the rare lung tumour entities encountered at a major thoracic surgery centre.
Zhejiang University · VerifiedLu Weiguo
gynaecological oncology pathology
Professor Lu Weiguo at Zhejiang First Affiliated is a gynaecological oncologist contributing to the molecular pathological characterisation of cervical, endometrial, and ovarian cancer in Chinese CSCO and GCIG clinical trials.
Zhejiang University · VerifiedHuang Jian
breast pathology
Dr Huang Jian at Zhejiang contributes to breast cancer histopathological diagnosis, TIL assessment, and HER2 testing within the Chinese CSCO breast cancer guidelines development process.
Zhejiang University · VerifiedLi Zhi
neuropathology
Dr Li Zhi at Zhejiang First Affiliated contributes to the WHO 2021 CNS tumour classification implementation, molecular marker testing for glioma diagnosis, and the neuropathological workup of DBS and epilepsy surgery specimens.
Zhejiang University · VerifiedChen Liang
bone pathology
Dr Chen Liang at Zhejiang contributes to bone and soft tissue tumour pathology at a major orthopaedic oncology centre, covering osteosarcoma resection histology and the diagnosis of primary bone lymphoma.
Zhejiang University · VerifiedWang Xian
haematopathology
Dr Wang Xian at Zhejiang contributes to haematopathology, covering bone marrow biopsy evaluation for AML, MDS, and lymphoma and the characterisation of EBV-associated haematological malignancies.
Zhejiang University · VerifiedFang Yu
skin pathology
Dr Fang Yu at Zhejiang contributes to dermatopathology and melanocytic lesion classification in Chinese patients, with attention to acral lentiginous melanoma which has a relatively higher proportion in Chinese melanoma cases than in Caucasian populations.
Zhejiang University · VerifiedTao Liang
urological pathology
Dr Tao Liang at Zhejiang contributes to prostate cancer Gleason grading, urothelial carcinoma staging, and the characterisation of renal oncocytoma and chromophobe RCC within the Zhejiang urological pathology network.
Zhejiang University · VerifiedZhang Xun
digital pathology AI
Dr Zhang Xun at Zhejiang University contributes to deep learning-based digital pathology, developing models for automated colon polyp grading and gastric cancer classification from whole-slide images.
Zhejiang University · VerifiedXu Yi
GI molecular testing
Dr Xu Yi at Zhejiang contributes to KRAS, NRAS, and BRAF mutation testing in Chinese colorectal cancer patients and the characterisation of BRAF V600E prevalence in Chinese serrated neoplasia.
Zhejiang University · VerifiedLi Hong
obstetric pathology
Dr Li Hong at Zhejiang Women's Hospital contributes to perinatal pathology, covering placental evaluation in preeclampsia, stillbirth, and preterm birth within the Zhejiang maternal mortality audit framework.
Zhejiang University · VerifiedYe Weiming
epidemiology pathology
Professor Ye Weiming at Zhejiang University contributes to molecular epidemiology of cancer, integrating pathological subtype data with environmental and genetic risk factor analysis in eastern Chinese cancer registry cohorts.
Zhejiang University · VerifiedTang Junfu
thoracic pathology
Dr Tang Junfu at Zhejiang contributes to the frozen section intraoperative diagnosis of thoracic masses and the sentinel lymph node evaluation in the context of minimally invasive lung cancer surgery.
Zhejiang University · VerifiedSun Guoping
thyroid pathology
Dr Sun Guoping at Anhui Provincial Hospital, with Zhejiang ties, contributes to the molecular pathological characterisation of thyroid cancer, including BRAF and TERT promoter co-mutation as a marker of aggressive behaviour.
Zhejiang University · VerifiedChen Weibing
infection pathology
Dr Chen Weibing at Zhejiang University contributes to the histopathological characterisation of viral hepatitis-associated liver disease progression, including the pathological correlates of HBV cure in clinical trial biopsies.
Zhejiang University · VerifiedLiu Wei
immunohistochemistry
Dr Liu Wei at Zhejiang contributes to the standardisation of immunohistochemistry laboratory practice in Chinese hospitals, including PD-L1 testing harmonisation and antibody clone comparison studies.
Zhejiang University · VerifiedWang Ruifen
lymphoma pathology
Dr Wang Ruifen at Zhejiang contributes to the diagnosis and molecular classification of lymphoma at a major eastern China haematopathology centre, with particular attention to aggressive B-cell lymphomas in Chinese adult patients.
Zhejiang University · Verified